81 results about "Personalized therapy" patented technology

The disclosed technology describes compositions and methods useful for providing cell based therapy. For example, one embodiment of cell based therapy involves the regeneration of injured tissue and / or promoting wound healing. Certain embodiments provide improved therapeutic compositions using microbubbles by delivering biological progenitor cells to the injured tissues. The administration of the microbubbles is directed by acoustic radiation forces that interact with embodiments of microbubbles comprising an acoustically active gas. As such, a high efficiency of progenitor cell delivery to injured tissue is realized. One advantage of this technique over targeted delivery of pharmaceutical compounds, is that the delivered progenitors cells may be derived from the patient (i.e., personalized therapy), thereby avoiding side effects, allergic reactions, and overall problems associated with refractive drug responses.

Methods, devices and systems for acquiring information useful to support a patient in implementing and adhering to a medically prescribed therapy plan are provided. The therapy may incorporate biofeedback methods and / or personalized therapy aspects. A method includes steps of receiving, by a receiving device, biometric information associated with an ingestible event marker; analyzing, by a computing device having a microprocessor configured to perform a biometric information analysis, the biometric information; and determining a therapeutic recommendation at least partly on the basis of the analysis and / or integrating biofeedback techniques into patient therapy or activity. A system includes a biometric information module to receive biometric information associated with an ingestible event marker; an analysis module to analyze the biometric information; and a determination module to optionally determine and communicate a therapeutic recommendation at least partly on the basis of the analysis.

The disclosed technology describes compositions and methods useful for providing cell based therapy. For example, one embodiment of cell based therapy involves the regeneration of injured tissue and / or promoting wound healing. Certain embodiments provide improved therapeutic compositions using microbubbles by delivering biological progenitor cells to the injured tissues. The administration of the microbubbles is directed by acoustic radiation forces that interact with embodiments of microbubbles comprising an acoustically active gas. As such, a high efficiency of progenitor cell delivery to injured tissue is realized. One advantage of this technique over targeted delivery of pharmaceutical compounds, is that the delivered progenitors cells may be derived from the patient (i.e., personalized therapy), thereby avoiding side effects, allergic reactions, and overall problems associated with refractive drug responses.

The present invention provides methods for personalized therapeutic management of a disease in order to optimize therapy and / or monitor therapeutic efficacy. In particular, the present invention comprises measuring an array of one or a plurality of biomarkers at a plurality of time points over the course of therapy with a therapeutic agent to determine a mucosal healing index for selecting therapy, optimizing therapy, reducing toxicity, and / or monitoring the efficacy of therapeutic treatment. In certain instances, the therapeutic agent is a TNFα inhibitor for the treatment of a TNFα-mediated disease or disorder.

The invention discloses a preparation method of pluripotent stem cells of a xeroderma pigmentosum patient. The method comprises the steps that by means of an iPSC technology, skin fibroblast cells of the xeroderma pigmentosum patient are reprogrammed into specific induced pluripotent stem cells through a non-integration episomal plasmid electrophoretic transfer method and directionally divided into nerve cells which show extreme sensitivities to UV in vitro, cell apoptosis is prone to occurrence, and some clues are provided for neurodegenerative diseases of the xeroderma pigmentosum patient. In addition, the mutational neural stem cells and neurones which carry genes of the patient can serve as an effective platform to conduct efficient and high-throughout personalized drug screening, and a foundation is laid for disease study, disease model development, research on pathogenesis of diseases and treatment on the diseases. A huge application prospect is achieved in personalized treatment and translational medicine.

Apparatus and Method adjusted to make Diagnosis and Therapy based on Non-Ionizing Radiations. It bases its function on the Nuclear Magnetic Resonance principle. It obtains a Quantitative Diagnosis integrating the following Devices: Manual Control Digital Filter / Selector (18), Frequency Matrix Monitor (25), Frequency Image Monitor (26) and Control Panel (28). The Therapy is achieved integrating the following devices: Radiofrequency resonator antenna (4), Radiofrequency low signal processor / Modulator (10), Radiofrequency pulse amplifier (13) and Central Pulse Control (16). The emission parameters of the emmision: Frequency, Power and Polarity are selectively manipulated to make it a Personalized Therapy. It substantially improves the levels of Selectivity and / or Differentiation of all the process. The Scientific, Technical and Commercial viability of the Invention is evident.

The present invention relates to a method of identifying, separating and characterizing a cell or a population of cells, by capturing at the cell surface, secreted soluble substances (such as an immunoglobulin) that cell or population of cell secrete. This is achieved by combing on a heterodimerically-tethered multispecific protein complex combining a binding specificity for the secreted molecule and a binding specificity for a surface antigen specific for that cell or population of cells. This method may be used in research and experimental purposes, such as patients' stratification in preparation of clinical trials or personalized therapies by identifying cell populations relevant to a pathology and / or prognosis.

The invention belongs to the technical field of biological medicines, and discloses application of an METTL2 gene in preparation of a kit for detecting the treatment sensitivity of colorectal cancer fluorouracil drugs. The application is based on the invention. The inventor discovers that METTL2 protein expression can enhance the sensitivity of colorectal cancer cells to 5-FU, and tumor tissue high expression METTL2 of a colorectal cancer patient is positively correlated with good prognosis of 5-FU chemotherapy. Therefore, a clinician can determine whether the colorectal cancer patient is suitable for fluorouracil drug treatment or not according to the expression condition of the METTL2 gene of the colorectal cancer patient, and formulate a personalized treatment scheme.

Methods and devices for clustering a plurality of sub-networks of a larger interaction network using an enhanced hierarchical clustering algorithm are disclosed. The methods provide expression based sub-network generation using differentially expressed markers. The enhanced hierarchical clustering algorithm clusters the generated sub-networks based on a user defined customizable similarity coefficient. The methods use non-Boolean links to cluster similar sub-networks. This provides consideration of indirect relationships among sub-networks. The customizable similarity coefficient enables the methods to be used for diverse applications such as biomarker detection, patient stratification, personalized therapy, drug efficacy prediction, genetic similarity analysis in genetic diseases. The methods enable patient grouping based on the enhanced hierarchical clustering algorithm.

The disclosure provides methods for treating a subject having a type I IFN-mediated disease or disorder comprising administration of a fixed does of an anti-interferon alpha receptor antibody. The disclosure also provides methods for suppressing a type I interferon (IFN) gene signature (GS) in a subject. In addition, the disclosure provides methods of prognosing or monitoring disease progression in a subject having a type I IFN-mediated disease or disorder, methods of predicting a dosage regimen, methods of identifying a candidate therapeutic agent, methods of identifying a patient as a candidate for a therapeutic agent, and methods of designating a personalized therapy.

Electronic arrangement (100) for use in providing therapeutic intervention to a user suffering from a medical condition, optionally to reduce fear of movement and improve function in patients with chronic pain, via virtual reality (VR) or augmented reality (AR), comprising a reproduction equipment (116) comprising a VR and / or AR projection device configured to represent virtual content, comprising an immersive virtual environment or a virtual part of a virtually augmented environment, to the user; user monitoring equipment (114, 114A, 114B) configured to obtain measurement data regarding the user, including motion, location, position, and / or biometric data; and a control system (118, 118A, 118B, 118C), at least functionally connected to the reproduction equipment and the user monitoring equipment, and configured to dynamically determine a personalized therapeutic program including the virtual content for representation via the reproduction equipment, based on the measurement data, wherein the therapeutic program comprises at least two domains of different virtual content, one or more of the domains involving behavior-change con-tent and at least one other domain involving user-activating virtual content indicative of a series of tasks to be conducted by the user having regard to the virtual content through associated therapeutic behavior, such as physical activity or problem solving, in the physical world outside the virtual environment or virtually augmented environment and tracked by the measurement data. A related method is presented.

The disclosure is directed to novel personalized therapies and methods for treating ankylosing spondylitis (AS). Specifically, this disclosure relates to methods of treating a patient having AS by selectively administering an IL-17 antagonist, e.g., an IL-17 antibody, such as secukinumab, to the AS patient on the basis of that patient being predisposed to have a favorable response to treatment with the IL-17 antagonist. Also disclosed herein are diagnostic methods and transmittable forms of information useful in predicting the likelihood that a patient having AS will respond to treatment with an IL-17 antagonist, e.g., an IL-17 antibody, such as secukinumab.

The present invention relates to providing a platform for predictive modeling of changes in composition of microbial communities upon exposure to changes or perturbations in the environment, more specifically the introduction of antimicrobial compounds, bacteriophages, or other agents that can be used for targeted or personalized therapy or microbiome remodeling. This platform has applications for human and animal health as well as environmental purposes.